• Hims & Hers Health, Inc. (NYSE:HIMS) has seen a significant 172% surge in its stock price in 2024, outperforming the healthcare sector.
• The company's Chief Commercial Officer, Chi Michael, sold 17,304 shares, yet the stock price remains robust with a recent close at $29.72.
• Upcoming earnings report (on February 24) anticipates a 1100% year-over-year growth in earnings per share and a 91.15% increase in revenue.

Hims & Hers Health, Inc. (NYSE:HIMS) is a leading telehealth company that has made a name for itself by providing access to prescription medications online, including popular GLP-1 drugs for weight loss. Despite not manufacturing these drugs, their availability has been a key growth driver for HIMS, positioning it as a competitive player in the healthcare sector.

On January 24, 2025, Chi Michael, the Chief Commercial Officer of HIMS, executed a significant transaction by selling 17,304 shares of Class A Common Stock at $31 each, leaving him with 193,601 shares. This move comes at a time when HIMS's stock price has shown resilience, closing recently at $29.72, despite a slight 0.3% decrease. This performance is noteworthy, especially when contrasted with the broader market gains, including the S&P 500's 0.61% increase, the Dow's 0.3% rise, and the Nasdaq's 1.28% gain.

The company has not only experienced a 5.9% increase in its stock price over the past month, outperforming the Medical sector's 1.64% gain and the S&P 500's 2.08% rise but also faced a decline of approximately 15% over the past month, indicating some investor withdrawal. Despite these fluctuations, HIMS remains a top performer in the healthcare sector, with a 172% share price surge in 2024.

As HIMS approaches its upcoming earnings report, investors are keenly awaiting the announcement of earnings of $0.12 per share, which would represent a significant 1100% year-over-year growth. Revenue is also projected to reach $471.42 million, marking a 91.15% increase compared to the same quarter last year. These projections and analyst forecast revisions will be crucial for investors looking to gauge the company's future performance.

Currently, HIMS's stock price stands at $30.87, with a slight decrease of 0.02, or approximately -0.0647%. The stock has seen fluctuations between $30.65 and $32.05 during the day, with a 52-week high of $35.02 and a low of $8.51. With a market capitalization of approximately $6.49 billion and a trading volume of 8,873,155 shares on the NYSE, HIMS continues to be a significant player in the telehealth industry.